Pharmaceutical Raw Material Rebamipide 99% CAS 90098-04-7

• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >98%
• Model NO.: TGY201906100702
• Product Name: Rebamipide
• Appearance: White Powder
• CAS No.: 90098-04-7
• Molecular Formula: C19h15cln2o4
• Molecular Weight: 370.79
• Assay: 99%
• Coa: Available
• Sample: Available
• MOQ: Any Quantitiy
• Service: OEM
• Grade: Pharmaceutical Grade
• Test Method: USP;GMP
• Storage: Cool Dry Area
• Shelf Life: 24 Months Properly
• Certificate: ISO9001:2008
• Transport Package: Boil Bag
• Specification: HPLC 99%
• Trademark: TGY
• Origin: Xi′an, Shaanxi, China (Mainland)
• HS Code: 29225090
• Production Capacity: 5000kg/Month

Product Description

The Leader Manufacturer of  Powder-TGY Bioteach

Pharmaceutical raw material Rebamipide 99% CAS 90098-04-7

 

Name	Rebamipide
CAS	90098-04-7
MF	C19H15ClN2O4
MW	370.79
MP	288-290°C dec.
Storage temp	-20°C Freezer
Assay	99% Min.
Appearance	White Powder
Usage	It is used for treating stomach ulcers. It is a kind of novel anti-ulcer drugs.

Rebamipide  an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating genes encoding cyclooxygenase-2.

Don't hesitate to contact us for latest COA

Rebamipide is used in a number of Asian countries including Japan, South Korea, and China. Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa, and more recently, the small intestine.

 

It has also been studied for the treatment of Behçet's disease.

 

It was shown to successfully treat pouchitis in a single-N study after first line therapies for the condition were unsuccessful.

 

Some studies have shown effectiveness in presbyacusis (age-related hearing loss).

 

It has also been shown to alleviate signs and symptoms of dry eyes in a randomised controlled trial although this is not yet widely available clinically.